CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis.

Autor: Reijman MD; Amsterdam UMC Location University of Amsterdam, Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, the Netherlands., van den Bosch SE; Amsterdam UMC Location University of Amsterdam, Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, the Netherlands., Kusters DM; Amsterdam UMC Location University of Amsterdam, Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, the Netherlands., Corpeleijn WE; Amsterdam UMC Location University of Amsterdam, Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, the Netherlands., Hutten BA; Amsterdam UMC Location University of Amsterdam, Department of Epidemiology and Data Science, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, the Netherlands., Kuipers IM; Amsterdam UMC Location University of Amsterdam, Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, the Netherlands., Planken RN; Amsterdam UMC Location University of Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, the Netherlands., Wiegman A; Amsterdam UMC Location University of Amsterdam, Department of Pediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, the Netherlands.
Jazyk: angličtina
Zdroj: Atherosclerosis plus [Atheroscler Plus] 2023 Dec 13; Vol. 55, pp. 1-4. Date of Electronic Publication: 2023 Dec 13 (Print Publication: 2024).
DOI: 10.1016/j.athplu.2023.12.002
Abstrakt: Familial hypercholesterolemia (FH) is one of the most common genetically inherited disorders in the world. Children with severe heterozygous FH (HeFH), i.e. untreated low-density lipoprotein cholesterol (LDL-C) levels above the 90th percentile for age and sex among FH mutation carriers, can have LDL-C levels that overlap levels of children with homozygous FH (HoFH), but treatment regimen and cardiovascular follow-up to prevent cardiovascular disease are less intensive in children with severe HeFH. In children with HoFH, subclinical atherosclerosis can already be present using computed tomography coronary angiography (CTCA). The question remains whether this is also the case in children with severe HeFH who have a high exposure to elevated LDL-C levels from birth onwards as well. We calculated the cumulative LDL-C exposure (CE total [mmol]) in four children with severe HeFH and performed computed tomography coronary angiography (CTCA). These children, aged 13, 14, 15 and 18 years, had CE total of 71.3, 97.8, 103.6 and 136.1 mmol, respectively. None of them showed abnormalities on cardiovascular imaging, despite high LDL-C exposure. The results of this study, do not give us an indication to recommend performing CTCA routinely in children with severe HeFH.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AW reports research support from pharmaceutical trials of lipid modification agents from Amgen, Regeneron, Novartis, 10.13039/100010137Sanofi, 10.13039/501100022336Esperion, 10.13039/501100022030Silence Therapeutics and Ultragenyx, and is a member of the safety board at Amryt. BAH and AW received a research grant from Silence Therapeutics. SEvdB, MDR, DMK, IMK, RNP and WEC have no conflicts of interest.
(© 2023 The Authors.)
Databáze: MEDLINE
Externí odkaz: